Rocket Pharmaceuticals (RCKT) announced that the FDA has accepted the resubmission of the biologics license application for Kresladi, a lentiviral vector-based investigational gene therapy for severe Leukocyte Adhesion Deficiency-I, a rare genetic immune disorder that predisposes patients to recurrent and fatal infections and is near-uniformly fatal in childhood without an allogeneic hematopoietic stem cell transplant. The PDUFA date set by the FDA is March 28, 2026.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCKT:
- Strategic Shift Towards Cardiovascular Platform Positions Rocket Pharmaceuticals for Future Growth
- Rocket Pharmaceuticals Board Member Resigns in September
- No jobs report amid shutdown, Apple pulls ICEBlock from App Store: Morning Buzz
- Rocket Pharmaceuticals price target lowered to $7 from $9 at Leerink
- Hold Rating on Rocket Pharmaceuticals Amid Strategic Shifts and Regulatory Challenges